Thus, with the intent to therapeutically target PRMT5 in the context of CLL at risk of RT, we developed tool compound PRT382 (Fig. 6a), a class of potent, selective PRMT5 inhibitors. This evidence concerns the gene PRMT5 and B-cell chronic lymphocytic leukemia.